Mike Narachi gets a $19M shot at a new approach to gene therapy — and he has another big market in mind
Mike Narachi is back at the helm of a startup biotech. And once again he’s taking on a big target market — with the help of a venture syndicate that has attracted some of the top corporate investors in the industry.
Narachi, you may recall, steered Orexigen through some huge development challenges to join a group of new weight loss drugs that debuted on the market. He survived the development risk and an initial FDA rejection, won a closely-watched approval and soldiered on to commercialization. And that’s where he and the team were decisively defeated — along with the others that tried and failed to find a niche for themselves.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
